Association of Elevated Amyloid and Tau Positron Emission Tomography Signal with Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

C Strikwerda-Brown; DA Hobbs; J Gonneaud; F St-Onge; AP Binette; H Ozlen; K Provost; JP Soucy; RF Buckley; TLS Benzinger; JC Morris; VL Villemagne; V Doré; RA Sperling; KA Johnson; CC Rowe; BA Gordon; J Poirier; JCS Breitner; S Villeneuve

Journal article

Association of Elevated Amyloid and Tau Positron Emission Tomography Signal with Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

C Strikwerda-Brown, DA Hobbs, J Gonneaud, F St-Onge, AP Binette, H Ozlen, K Provost, JP Soucy, RF Buckley, TLS Benzinger, JC Morris, VL Villemagne, V Doré, RA Sperling, KA Johnson, CC Rowe, BA Gordon, J Poirier, JCS Breitner, S Villeneuve

JAMA Neurology | Published : 2022

DOI: 10.1001/jamaneurol.2022.2379

Abstract

Importance: National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD). Objective: To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-term risk of developing symptomatic AD. Design, Setting, and Participants: This longitudinal cohort study used data from 4 independent population-based cohorts (PREVENT-AD, HABS, AIBL, and Knight ADRC) collected between 2003 and 2021. Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid β ..

View full abstract

University of Melbourne Researchers

Rachel Buckley Author

Victor Villemagne Author

Christopher Rowe Author

Paul Maruff Author

Related Projects (2)

Tracking the development of Alzheimer's disease with beta amyloid imaging

A new scan called PiB PET shows the build up of amyloid protein deposits in the brain in all patients with Alzheimer's disease (AD) but also..

THE PREVALENCE OF ALZHEIMER'S DISEASE PATHOLOGY AFTER TRAUMATIC BRAIN INJURY IN VETERANS AND CIVILIANS: A BIOMARKER STUDY OF BETA-AMYLOID AND TAU

PUBLIC ABSTRACT Background: Some old research studies have suggested that people with brain injuries maybe 400% more likely to lose their ..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

Dr Strikwerda-Brown is supported by a joint postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR), Alzheimer's Society of Canada (ASC), and Fonds de Recherche du Quebec-Sante. Dr Hobbs is supported by the National Institutes of Health (NIH). Dr Gonneaud was supported by the StoP-AD Center, Quebec Bio-Imaging Network, Fondation Alzheimer, and Fondation de France. Mr St-Onge is supported by the Canada First Research Excellence Fund and Fonds de Recherche du Quebec, awarded to the Healthy Brains, Healthy Lives initiative at McGill University. Dr Binette is supported by a Brightfocus Foundation postdoctoral fellowship. Dr Buckley is supported by a K99/R00 award from the National Institute on Aging (R00AG061238-03) and an Alzheimer's Association Research Fellowship (AARF-20-675646). Dr Gordon is supported by the Alzheimer's Association and NIH. Dr Villeneuve is supported by a Canada Research Chair and a Canada Fund for Innovation grant. PREVENT-AD was funded by the CIHR, Alzheimer's Association, ASC, Brain Canada, McGill University, the government of Canada, an unrestricted gift from Pfizer Canada, the Canada Fund for Innovation, the Douglas Hospital Research Centre, and the Levesque Foundation, and Genome Quebec Innovation Center.